An evaluation of ibrexafungerp for the treatment of invasive candidiasis: the evidence to date.

INTRODUCTION: Invasive fungal infections, especially candidemia and invasive candidiasis, cause significant morbidity and mortality. The epidemiology of candida infections have changed dramatically due to an increase in risk factors associated with the development of infection and the emergence of resistant isolates such as C. glabrata and C. auris . This has prompted the search for novel and effective antifungals.

AREAS COVERED: The results of in vitro studies evaluating the activity of ibrexafungerp against Candida species are reviewed and the pharmacokinetic/pharmacodynamic properties are highlighted. Available results and safety data from limited clinical studies are discussed.

EXPERT OPINION: Ibrexafungerp demonstrates potent in vitro activity against susceptible and resistant Candida species, including echinocandin-resistant C. glabrata and multidrug-resistant C. auris . It also offers the flexibility of a parenteral and an oral preparation, minimal adverse effects, and low drug-drug interactions. In Phase 2/3 clinical trials, ibrexafungerp appears to have excellent clinical activity in patients with candidemia, invasive candidiasis, and mucosal candidiasis. Although there are several ongoing clinical trials, ibrexafungerp appears to be a promising agent and an important addition to the antifungal armamentarium necessary to treat emerging and resistant pathogens, including several of the Candida species.